CD8+ tumor-infiltrating T-cell levels were higher on treatment in responders than in non-responders, and T-cell expansion by end of the first cycle was more pronounced in responders than in non-responders, irrespective of baseline CD8+ T-cell levels (208). The gene discussed is CD8A; the disease is neoplasm.